Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983293 | 0.91 | P2RX7 (0.55) | EPHX2SSTR4P2RX7ALDH1A1 | |
| SCHEMBL4981471 | 0.81 | ALDH1A1 (0.64) | EPHX2SSTR4P2RX7ALDH1A1MCHR1 | |
| SCHEMBL4981042 | 0.80 | HPGD (0.53) | SSTR4MCHR1DRD4HPGDRAB9A | |
| SCHEMBL4980687 | 0.80 | HPGD (0.52) | EPHX2SSTR4ALDH1A1MCHR1DRD4 | |
| SCHEMBL14263124 | 0.80 | MCHR1 (0.48) | EPHX2SSTR4MCHR1DRD4HPGD | |
| SCHEMBL4982809 | 0.79 | DRD4 (0.49) | EPHX2SSTR4P2RX7ALDH1A1MCHR1 | |
| SCHEMBL14263136 | 0.79 | HPGD (0.51) | SSTR4ALDH1A1MCHR1DRD4HPGD | |
| SCHEMBL4983041 | 0.76 | EPHX1 (0.52) | EPHX2SSTR4MCHR1DRD4HPGD | |
| SCHEMBL4975820 | 0.76 | EPHX1 (0.52) | EPHX2P2RX7MCHR1DRD4HPGD | |
| SCHEMBL4979013 | 0.75 | ALDH1A1 (0.73) | EPHX2SSTR4P2RX7ALDH1A1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | EPHX2 2001/4885SSTR4 654/4885P2RX7 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.